HomeThemesTypesDBAbout
Showing: ◈ medicine×
President will put US firms first in UK trade talks, says Kim Darroch
The paper, commissioned by the Scottish Government, identified 137 potential impacts.
A review of evidence about opportunities, challenges and risks to the North East economy and its key sectors with recommendations for action.
The UK must ensure that it retains access to the Single Market, has an open trading regime and maintains a stable regulatory framework with the European Union to minimise the impact of Brexit on the North East economy. This is the key conclusion of ‘Leaving the European Union’, a report by a powerful regional economic group says today.
Ministers will relax rules around clinical trials and streamline the approval of new medicines in a bid to maintain Britain’s competitiveness following Brexit.
When President Donald Trump arrived in the United Kingdom this week, he landed bang in the middle of a huge political fight about the country's National Health Service.
Brian Toohey, of the Pharmaceutical Research and Manufacturers of America trade group, spearheads PhRMA and recently told of the US drugs industry's predatory intentions.
This video from January is US Pharma industry lobby telling US trade negotiators that US-UK trade deal is “an important opportunity” to deal with “artificially depressed prices” in UK - “dictated” via our “primary payer” system
A US-UK trade deal is being negotiated, and drug prices are a key issue. Several US officials are demanding that foreign countries pay higher prices to US drug companies.
Post-Brexit, the cost of medicines they rely on could skyrocket.
Asked if Washington would be free to ‘jack up prices’, Foreign Secretary Dominic Raab replies ‘The Americans will take their decisions’.
George Hollingbery, then trade minister, and John Saville, Her Majesty’s Consul General in Chicago met a pharmaceutical company's senior director in August last year to discuss a post-Brexit pact.
Labour leader says documents leave Boris Johnson’s denials on post-Brexit US trade deal ‘in tatters’.
I spoke up on the dangers of medicine supply plans for No-Deal Brexit, but was ignored by my MP Sajid Javid. So now I'm running against him.
Envoys sidestep ban on discussing drug prices by referring to controversial subject ‘valuing innovation’.
Tahir Amin is a British lawyer based in America who is an expert on drug pricing and on previous trade negotiations.
‘This is clearly an attempt to make it harder for the public and parliament to ensure protections are not traded away’
Brexit could have major implications for health and social care in England. Here we look at some of the latest developments that could have an impact.
SCOTLAND'S two chief medical officers has issued a new warning of shortages to the supply of medicines in the event of a 'no deal' Brexit.
Those on the frontline are caught between political uncertainty and a scared and sometimes angry public.
Professor Dame Sally Davies said shortages of medical supplies will put lives at risk.
Four companies agree contracts that will help ensure supply of vital medicines.
The government is facing an unprecedented backlash from five key industries over Boris Johnson's plans for post-Brexit trading arrangements.
England's Chief Medical Officer Professor Dame Sally Davies warned that a no-deal Brexit could lead to "deaths", amid suggestions the Government could adopt leaving the EU without a deal as an official position in an election.